As of November 6, 2026, Plus Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 9, 2026 (Form 8-K, April 9, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Plus Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Plus Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-09. Every row below is cited to the filing it comes from, and this page adds each new change as Plus Therapeutics, Inc. files it.
Also on the record for Plus Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 18, 2026 | Form D, private offering | $3M sold | Form D page | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Highbridge Capital Management, LLC | 7.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 4.9% of the class | 5%+ stakes | Source |
| January 22, 2026 | Stake report, Schedule 13G, by CVI Investments, Inc. | 6.9% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by S.H.N. Financial Investments Ltd. | 1.51% of the class | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G/A, by Orin Hirschman | 3.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Plus Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Plus Therapeutics, Inc. and the records around it.
Plus Therapeutics, Inc. elsewhere on the record
- Form D filing Sep 2026
- Who owns it
Companies that share a holder
- S.H.N. Financial Investments Ltd. also filed stake reports on 19 other companies: PRF Technologies Ltd. (Nov 2026), INLIF Ltd (Oct 2026), DarkIris Inc. (Oct 2026)
- Orin Hirschman also filed stake reports on 46 other companies: ASPEN AEROGELS, INC. (Oct 2026), Bionano Genomics, Inc. (Oct 2026), FENNEC PHARMACEUTICALS INC. (Oct 2026)
- CVI Investments, Inc. also filed stake reports on 48 other companies: Pine Tree Acquisition Corp. (Oct 2026), Sunshine Biopharma Inc. (Oct 2026), Outlook Therapeutics, Inc. (Aug 2026)
Watch Plus Therapeutics, Inc.
Get an email when Plus Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Plus Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Plus Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Plus Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-09 | Reported | not named in the filing | 8-K, 2026-04-09 |
New leaders reset buying decisions — get the Full Report on Plus Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Plus Therapeutics, Inc., with the record behind each one.
Find candidates like senior executive at Plus Therapeutics, Inc.Every change, in the filing's words
Reported
Appointment of Eric J. Daniels, M.D. as Chief Development Officer On April 9, 2026, Plus Therapeutics, Inc. (the "Company") announced the appointment of Dr. Eric J. Daniels as Chief Development Officer of the Company, effective April 20, 2026.
- Dr. Daniels, age 53, will be responsible for the development and ultimate approval of the Company's pharmaceutical pipeline effective upon the commencement of his employment with the Company.
- Prior to joining the Company, from October 2021 through April 2026, Dr. Daniels served as the chief development officer of Kiora Pharmaceuticals (NASDAQ:KPRX).
- In addition, from 2018 through 2021, Dr. Daniels served as the executive director and co-founder of Bayon Therapeutics until it was acquired by Kiora Pharmaceuticals in October 2021 and as chief executive officer of OccuRx Pty Ltd., a clinical stage biotechnology company targeting microvascular disease for ocular indications, from July 2020 through October 2021.
- Dr. Daniels is also a co-founder and director of Okogen, Inc., a specialty biotechnology development stage ophthalmic company focused on a novel therapeutic for the treatment of viral infections of the eye, since May 2016.
- Since January 2014, Dr. Daniels has served on the clinical advisory board of Bimini, LLC and was chief medical officer of Bimini from January 2014 to October 2021.
- From April 2012 to November 2016, Dr. Daniels served as vice president - marketing & sales for Tensys Medical, Inc. (an HBM portfolio company).
Tools for this story
Each opens in a new tab, filled in for Plus Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.